#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	16398	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2070	786.8	0	.	n	.	0	C451T	SNP	451	451	C	697	697	T	955	T,C	437,427	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	16398	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2070	786.8	1	SNP	n	C1184T	0	.	.	1184	1184	C	1430	1430	C	970	C	859	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	30414	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3587	845.6	0	.	n	.	0	T695C	SNP	695	695	T	1054	1054	C	930	C,T	821,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	30414	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3587	845.6	0	.	n	.	0	A1638G	SNP	1638	1638	A	1997	1997	G	918	G,A	626,210	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	30414	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3587	845.6	0	.	n	.	0	T1971C	SNP	1971	1971	T	2330	2330	C	966	C,T	870,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	30414	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3587	845.6	1	SNP	n	A2045G	0	.	.	2045	2045	A	2404	2404	A	1006	A	915	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	30414	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3587	845.6	1	SNP	n	C2597T	0	.	.	2597	2597	C	2956	2956	C	930	C,G	856,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_O_01412c	folP.WHO_O_01412c	1	1	27	2310	folP	855	855	100.0	folP.l15.c17.ctg.1	1382	166.1	1	SNP	p	R229S	1	.	.	685	687	AGC	936	938	AGC	267;269;268	A;G;C	243;245;242	folP.WHO_O_01412c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	6232	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3412	181.9	1	SNP	p	S91F	1	.	.	271	273	TTC	566	568	TTC	215;214;217	T;T;C	194;191;190	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	6232	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3412	181.9	1	SNP	p	D95G	1	.	.	283	285	GGC	578	580	GGC	216;214;214	G;G;C	191;192;189	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	6232	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3412	181.9	1	SNP	p	G95N	0	.	.	283	285	GGC	578	580	GGC	216;214;214	G;G;C	191;192;189	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	27	1798	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1255	142.4	1	SNP	p	G45D	0	.	.	133	135	GGC	450	452	GGC	256;255;254	G;G;C	225;227;225	mtrR.WHO_O_01438:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	882	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1100	80.0	0	.	n	.	0	A197.	DEL	197	197	A	555	555	A	235	A	214	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5496	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2944	186.2	1	SNP	p	D86N	0	.	.	256	258	GAC	532	534	GAC	217;217;213	G;A;C,T	192;193;195,1	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5496	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2944	186.2	1	SNP	p	R87I	0	.	.	259	261	CGT	535	537	CGT	213;215;217	C;G;T	196;198;196	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5496	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2944	186.2	1	SNP	p	S87R	1	.	.	259	261	CGT	535	537	CGT	213;215;217	C;G;T	196;198;196	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5496	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2944	186.2	1	SNP	p	R87W	0	.	.	259	261	CGT	535	537	CGT	213;215;217	C;G;T	196;198;196	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5496	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2944	186.2	1	SNP	p	S88P	0	.	.	262	264	TCC	538	540	TCC	216;215;216	T;C;C	197;195;197	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4930	parE	1986	1986	100.0	parE.l6.c4.ctg.1	2523	194.6	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1518	1520	GGC	237;239;235	G;G;C	207;208;204	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.34.001	penA.34.001	1	1	27	4588	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2359	193.6	1	SNP	p	A311V	0	.	.	931	933	GCC	1286	1288	GCC	286;285;289	G;C,T;C,G	251;250,1;255,1	penA.34.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4588	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2359	193.6	1	SNP	p	I312M	1	.	.	934	936	ATG	1289	1291	ATG	293;291;294	A;T;G	259;260;258	penA.34.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4588	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2359	193.6	1	SNP	p	T316P	0	.	.	946	948	ACC	1301	1303	ACC	287;287;288	A;C;C	251;253;256	penA.34.001:1:1:T316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4588	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2359	193.6	1	SNP	p	V316T	1	.	.	946	948	ACC	1301	1303	ACC	287;287;288	A;C;C	251;253;256	penA.34.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4588	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2359	193.6	1	SNP	p	T483S	0	.	.	1447	1449	ACC	1802	1804	ACC	241;243;243	A;C,T;C	203;209,1;211	penA.34.001:1:1:T483S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4588	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2359	193.6	1	SNP	p	A501P	0	.	.	1501	1503	GCG	1856	1858	GCG	220;221;227	G;C;G	194;196;201	penA.34.001:1:1:A501P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4588	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2359	193.6	1	SNP	p	A501V	0	.	.	1501	1503	GCG	1856	1858	GCG	220;221;227	G;C;G	194;196;201	penA.34.001:1:1:A501V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4588	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2359	193.6	1	SNP	p	G542S	0	.	.	1624	1626	GGT	1979	1981	GGT	201;200;198	G;G;T	184;181;177	penA.34.001:1:1:G542S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4588	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2359	193.6	1	SNP	p	G545S	1	.	.	1633	1635	AGC	1988	1990	AGC	190;188;187	A,G;G;C	169,1;169;168	penA.34.001:1:1:G545S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4588	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2359	193.6	1	SNP	p	P551S	0	.	.	1651	1653	CCG	2006	2008	CCG	157;159;155	C,G;C,G;G	116,8;121,1;118	penA.34.001:1:1:P551S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	6322	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3156	199.7	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1664	1666	CCG	227;231;230	C;C;G	200;203;199	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2382	porA	1146	1146	99.91	porA.l15.c4.ctg.1	1805	131.6	0	.	p	.	0	M83fs	FSHIFT	247	247	A	510	510	C	177	C	156	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	27	3196	porB1b	1038	1038	100.0	porB1b.l6.c4.ctg.1	1546	205.4	1	SNP	p	G120K	1	.	.	358	360	AAG	646	648	AAG	274;270;267	A;A;G	250;250;243	porB1b.WHO_Y_02277c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	27	3196	porB1b	1038	1038	100.0	porB1b.l6.c4.ctg.1	1546	205.4	1	SNP	p	N121D	0	.	.	361	363	AAC	649	651	AAC	266;268;266	A;A;C	244;247;243	porB1b.WHO_Y_02277c:1:1:N121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	27	3196	porB1b	1038	1038	100.0	porB1b.l6.c4.ctg.1	1546	205.4	1	SNP	p	A121N	1	.	.	361	363	AAC	649	651	AAC	266;268;266	A;A;C	244;247;243	porB1b.WHO_Y_02277c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	12226	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	4814	253.3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1298	rpsJ	312	312	100.0	rpsJ.l6.c4.ctg.1	964	133.2	1	SNP	p	V57M	1	.	.	169	171	ATG	576	578	ATG	281;278;270	A;T;G,A	256;248;239,2	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
